Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.32 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6394181 | 0.85 | EPHX2 (0.30) | — | |
| SCHEMBL6387745 | 0.80 | ACLY (0.46) | GUCY1A1GUCY1B1ACLYACACBACACA | |
| Cyanamide SCHEMBL6354571 | 0.79 | ACLY (0.35) | ACLYACACBACACA | |
| Cyanamide SCHEMBL6346397 | 0.77 | ACLY (0.37) | ACLYACACBACACA | |
| SCHEMBL6394273 | 0.75 | ACLY (0.48) | GUCY1A1GUCY1B1ACLYACACBACACA | |
| SCHEMBL6389106 | 0.75 | ACACB (0.43) | GUCY1A1GUCY1B1ACLYACACBACACA | |
| Cyanamide SCHEMBL6709922 | 0.75 | ACLY (0.33) | ACLYACACBACACA | |
| SCHEMBL6745449 | 0.74 | ACLY (0.38) | GUCY1A1GUCY1B1ACLYACACBACACA | |
| Cyanamide SCHEMBL6392049 | 0.73 | FFAR1 (0.37) | — | |
| SCHEMBL6394178 | 0.73 | CA14 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192347-A1 | Urea and thiourea compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2005-09-01 | — | — | US | claimed |
| WO-2005068420-A1 | UREA AND THIOUREA COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192347-A1 | Urea and thiourea compounds and compositions for cholesterol management and related uses | PNLIP, FABP2, GPR119 | GUCY1A1 2207/4885GUCY1B1 1796/4885ACLY 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.